Document is current
Any future updates will be listed below
-
Authors
Peeters, L. E. J.
Kappers, M. H. W.
Boersma, E.
Massey, E. K.
van Dijk, L.
van Gelder, T.
Koch, B. C. P.
Versmissen, J.
- License Information
-
More Information
Article History
Received: 4 January 2023
Accepted: 6 February 2023
First Online: 14 February 2023
Declarations
:
: This study was approved by the Institutional Review Board (IRB) of the Erasmus MC, University Medical Centre, Rotterdam, the Netherlands (MEC-2018–027). Written informed consent will be obtained of every participant before start of the study.
: Not applicable.
: L.E.J. Peeters has received lecture fees from Astellas Pharma in 2021. T. van Gelder has received lecture fees and study grants from Chiesi and Astellas, in addition to consulting fees from Roche Diagnostics, Thermo Fisher, Vitaeris, CSL Behring, Astellas and Aurinia Pharma. In the last 3 years L. van Dijk has received a research grant from Teva for a study not related to this one. M.H.W. Kappers, E. Boersma, E.K. Massey, B.C.P. Koch and J. Versmissen have no conflicts of interest.
